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S70 ABSTRACTSMaterials and methods: From August 2013 until January 2014, physi-
cians working in multidisciplinary BC teams (5 years BC treatment experi-
ence) could complete the online survey. Some modules evaluated respondent
demographics and clinical tools used for AdjCT decision-making. For anal-
ysis, the physicians were categorized into 3 groups: clinical/medical oncolo-
gists, surgeons and gynecologists (S&G) who prescribe AdjCT (S&G
AdjCT+), and S&G who do not prescribe AdjCT (S&G AdjCTe).
Results: Overall, 911 respondents (52countries) completed the survey;
829 respondents were included in this analysis.
S&G seemed to use MGA more often than medical/clinical oncolo-
gists. Among MGA users in all 3 groups Oncotype DX was used the
most, followed by MammaPrint,and EndoPredict (mainly German gy-
necologists). For those who did not use MGA,>85%of respondents in all 3
physician groups would like to incorporate MGA in their practice, and
various reasons for non-use of MGA were reported. The heterogeneity of
MGA adoption in relation to specialty of the physician may be partly
related to the heterogeneity in MGA adoption observed between countries.
Conclusions: The MAGIC survey showed that S&G used MGA more
often than medical/clinical oncologists and that there are differences in the
MGA they use and their reasons for not using MGA.
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Usage of tools (overall)
Adjuvant! Online 74% 75% 66%
Nottingham Prognostic Index 17% 15% 32%
Predict 12% 11% 11%
Usage of MGA
Overall 47% 69% 69%
>20% of their HR+, HER2e,
lymph nodee BC pts
(% of MGA users)
32% 43% 45%
>20% of their HR+, HER2e,
lymph node+ BC pts
(% of MGA users)
20% 36% 34%
Used assays
(% of MGA users)
Oncotype DX 77% 82% 80%
MammaPrint 38% 9% 39%
EndoPredict 3% 28% 2%
Reasons for not using MGA
(% of MGA nonusers)
Lack of reimbursement 48% 57% 28%
Price 39% 60% 55%
No availability 41% 27% 38%
Not in relevant guidelines 19% 17% 26%
Lack of evidence 16% 30% 16%http://dx.doi.org/10.1016/j.ejso.2014.08.153159. Comparison of hormone receptor and HER2 assay results
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Purpose: In the treatment of breast cancer, hormone receptor (HR)
expression and HER2 (human epidermal growth factor receptor 2) gene
expression are the most important biomarkers. Therefore, the accuracy
of their results is critical.
Subject and methods: We studied the results of HR expression and
HER2 gene expression of 153 consecutive patients between March 2009
and February 2014. Estrogen receptor(ER), progesterone receptor (PgR)
and HER2 gene immunohistochemical(IHC) assay of tissues from mastec-
tomy specimens were compared with their previous core needle biopsy
(CNB) ER, PgR and HER2 gene IHC assay results.
Results: The tumors of 112(73.2%) out of the 153 patients are positive
HR(ER and/or PgR) in CNB specimens and 107(69.9%) are positive HR in
mastectomy specimens. 33(21.6%) patients are positive HER2 in CNB speci-
mens and 34(22.2%) are positiveHER2 inmastectomy specimens. ERpositiv-
ity decreased from 71.9% in the CNB to 68.0% in mastectomy specimens,
while PgR positivity increased from 60.8% in the CNB to 64.7% in mastec-
tomy specimens. The overall agreement between CNB and mastectomy spec-
imens was 92.1% for ER, 86.9% for PgR and 98.0% for HER2.
Conclusion: CNB specimens are associated with the identification of
more frequent and higher levels of hormonal receptor proteins than mas-
tectomy specimens. However, there are CNB negative and mastectomy
positive disagreements in HR and HER2 cases. Proper hormonal therapy
depends on accurate hormone receptor assay results, as well as target ther-
apy depends on HER2 assay results. Both assays of CNB and mastectomy
specimens are very helpful in accurate ER, PgR and HER2 assay results.
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Background: Magnetic sentinel lymph node biopsy (SLNB) is in its
early stages of clinical application. We developed an in vivo porcine model
to optimise the magnetic technique by evaluating the effect of differing
volume of magnetic tracer and time of injection.
Materials and Methods: Magnetic tracer was injected in escalating
volumes between 0.06 mL and 2 mL neat. A handheld magnetometer
was then used to localize any in vivo signal from draining inguinal lymph
nodes up to 4 hours after injection when bilateral magnetic SLNB of groin
nodes was consequently undertaken, followed by groin node clearance.
The iron content of excised sentinel lymph nodes (SLNs) was quantified
and univariate analyses performed to assess correlation.
Results: Magnetic SLNB was successful in all 48 procedures. There
was a significant correlation between the magnetometer counts and the
iron content of excised SLNs (r¼0.82; p<0.001). Total number of SLNs
increased with increasing volumes of magnetic tracer (P<0.001). Transcu-
taneous magnetometer counts increased with increasing time from injec-
tion of magnetic tracer (P<0.0001) and reached a plateau within 60
ABSTRACTS S71minutes. A non-statistically significant trend was observed between vol-
ume of magnetic tracer injected and iron content of SLNs (P¼0.07).
Conclusion: Magnetic SLNB is feasible with a range of volumes of
magnetic tracer. The manipulation of volumes of magnetic tracer injected
can determine the level of echelon nodes excised and increasing the time
between injection and SLNB improves transcutaneous ’hotspot’ identifica-
tion. Application of these findings may help to improve clinical outcomes.
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Background: Magnetic sentinel lymph node biopsy (SLNB) is an
emerging technique in the axillary staging of breast cancer. There is no ev-
idence available to determine a suitable threshold of ex vivo magnetometer
counts for node excision. Consequently, the ‘10 per cent rule’ derived from
radioisotopes is applied. We assess the largest study of magnetic SLNB
(SentiMAG Multicentre Trial) to determine the validity of the ’10 per
cent rule’.
Materials and methods: A total of 347 patients across 7 centres un-
derwent SLNB with both magnetic and standard techniques. The ex vivo
counts and histopathology of all nodes was prospectively collected. The
distribution of magnetometer and radioactive counts of all nodes was as-
sessed. The nodes excised for each patient were then classified as a per-
centage of the node with the highest count (hottest node). The false
negative rates (FNR) as a decreasing function of the threshold of magne-
tometer and radioactive counts was examined.
Results: A total of 855 nodes were excised of which 747 were identi-
fied using the magnetic and 794 using the standard technique. The peak
distribution of counts for all nodes using both techniques was in the range
0-500. The majority of metastatically involved nodes had the highest mag-
netic (62 per cent) and radioactive (58 per cent) uptake. The application of
the 10 per cent threshold resulted in a false negative rate of 0 per cent
versus 2.8 per cent for the magnetic and radioisotope techniques
respectively.
Conclusion: The ‘10 per cent rule’ of the hottest ex vivo node is an
acceptable threshold for the safe performance of magnetic SLNB.
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Background: Portable ultrasound is now used in a variety of clinical
settings by specialties outside of radiology. Despite increased accessibility
to ultrasound the overall performance of ultrasound by breast surgeons is
consistently low. We discuss the reasons why this is unacceptable for
future patient care and answer the question, ’Why should breast surgeons
use ultrasound?’
Methods: We reviewed the literature for evidence assessing the out-
comes of breast surgeon-performed ultrasound both intra-operatively and
in the outpatient department.Results: Intra-operative ultrasound (IOUS) performed by surgeons re-
duces re-excision rates in breast conserving surgery. Outpatient-based ul-
trasound performed by surgeons frees up the resources of radiology
departments, allowing them to focus upon patients requiring more complex
diagnostic and interventional procedures. For surgeons to competently
perform intra-operative and outpatient-based ultrasound a period of formal
ultrasound training is necessary to acquire knowledge of ultrasound skills
and techniques. This should be followed by a period of mentorship and su-
pervised training with an experienced breast radiologist.
Conclusions: Breast surgeon-performed ultrasound is beneficial to the
multi-disciplinary care of breast cancer patients. To further improve multi-
disciplinary care, breast surgeons and radiologists should work more
collaboratively to optimise imaging applications both in the operating
theatre and outpatient department. Current advances in therapeutic percu-
taneous techniques are of interest to both surgeons and radiologists. In
future a hybrid specialization should be considered to incorporate accred-
itation in both specialties for breast interventional procedures.
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Introduction: Breast cancers (BC) in males are rarely diagnosed and
comprise about 1% of all BC pts.
Patients and methods:We analyzed a group of male BC pts who were
treated at the Institute of Oncology and Radiology of Serbia from 1994 to
2010. The majority of them were operated on depending on disease stage
at diagnosis and (neo)adjuvant chemotherapy [(N)ACT] with CMF and
FAC and Tamoxifen were given where indicated. Postoperative radio-
therapy was performed in all N+ and T4 BC pts. Hormone receptors
(HR) were determined prospectively either by biochemical DCC method,
or by immunohistochemistry (IHC), while HER2 status was determined by
IHC. Study endpoints were PFS, DFS and OS. Statistics includes Hi square
and Log rank tests.
Results: In total 110 male pts median ages of 65 (range 29-84) years
were analyzed. After median follow-up period of 56.6 mos (range 5-199
mos) disease relapse were confirmed in 42/110 (38%) pts, while 55/110
(50%) died. Sixty three pts (57%) were diagnosed in stage I/II, 86/110
(78%) had ductal invasive and 81/110 (74%) grade 2 BC. HRs were deter-
mined in 68/110 (62%) pts and among them 63/68 (93%) were ER+ and/or
PR+, while HER2 status was negative in 21/21 pts in whom it was
measured (only 2/21 were triple neg BC). Radical surgery was performed
in 87/110 (79%) of pts, radiotherapy in 77/110 (70%) of pts, (N)ACT
received 45/110 (42%) and Tamoxifen 71/110 (66%) of pts. The following
factors significantly influenced the disease outcome: a) stage 1/2 vs. stage
3 at diagnosis: longer DFS (Log-Rank test, p¼ 0.0), PFS (p¼ 0.0) and OS
(p¼ 0.0); b) T 1/2 vs. T3/4: longer DFS (p¼ 0.005), PFS (p¼ 0.0) and OS
(p¼ 0.0); c) number of involved regional lymph nodes in radically oper-
ated pts: N0 vs. N 34 longer DFS (p<0.0001), PFS (p<0.0001) and OS
(p¼ 0.0001) and N1-3 vs. N 34: longer DFS (p¼ 0.007) and PFS (p¼
0.01). Patients who were radically operated had better disease outcome
compared to pts w/o radical surgery: longer PFS (p¼ 0.011) and OS
(p¼ 0.002). Type of systemic therapy and radiotherapy did not influence
disease outcome. Similarly, PR status did not influenced disease outcome
in ER+ BC pts.
Conclusion: Endocrine responsiveness was shown in a majority of pts
with known HRs and luminal A/B subtypes were detected in almost all pts
with known HER2 status. Our results confirmed that stage of disease at
diagnosis, radical surgery and nodal status in operated pts are the most
important factors influencing disease outcome.
